<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="cell is the first step in the formation of all" exact="viral" post="diseases. Controlling viral infections by disrupting viral entry is"/>
 <result pre="first step in the formation of all viral diseases. Controlling" exact="viral" post="infections by disrupting viral entry is advantageous for antibody-mediated"/>
 <result pre="step in the formation of all viral diseases. Controlling viral" exact="infections" post="by disrupting viral entry is advantageous for antibody-mediated neutralization"/>
 <result pre="formation of all viral diseases. Controlling viral infections by disrupting" exact="viral" post="entry is advantageous for antibody-mediated neutralization by the host’s"/>
 <result pre="its carbohydrate-binding capability. Its in vitro antiviral profiles against human" exact="immunodeficiency" post="virus (HIV) are also discussed followed by a description"/>
 <result pre="of action are provided in conjunction with an explanation of" exact="viral" post="resistance profiles to GRFT. In addition, its in vitro"/>
 <result pre="effects on viruses are presented. griffithsin (GRFT) lectin carbohydrate-binding human" exact="immunodeficiency" post="virus (HIV) microbicide virus entry inhibitor 1. Introduction Every"/>
 <result pre="with different receptor association capabilities. The best-characterized example of this" exact="viral" post="glycoprotein–host cell receptor relationship might be the interaction between"/>
 <result pre="cell receptor relationship might be the interaction between the human" exact="immunodeficiency" post="virus (HIV) glycoprotein gp120 and the human T lymphocyte"/>
 <result pre="to its essential role in the overall virus life cycle," exact="viral" post="entry has been an attractive target for both vaccine"/>
 <result pre="drug development with the goal of disrupting the binding of" exact="viral" post="glycoproteins to host cell receptors. In addition, heavy and"/>
 <result pre="In addition, heavy and unique glycosylation patterns found only on" exact="viral" post="glycoproteins provide another level of virus specificity, which could"/>
 <result pre="against HIV began during the epidemics of the early 1980s." exact="HIV infection" post="was linked with the development of acquired immune deficiency"/>
 <result pre="HIV began during the epidemics of the early 1980s. HIV" exact="infection" post="was linked with the development of acquired immune deficiency"/>
 <result pre="early 1980s. HIV infection was linked with the development of" exact="acquired" post="immune deficiency syndrome (AIDS). With no effective antiviral drugs"/>
 <result pre="HIV infection was linked with the development of acquired immune" exact="deficiency" post="syndrome (AIDS). With no effective antiviral drugs available during"/>
 <result pre="infection was linked with the development of acquired immune deficiency" exact="syndrome" post="(AIDS). With no effective antiviral drugs available during that"/>
 <result pre="effective antiviral drugs available during that time, a diagnosis of" exact="HIV infection" post="was a death sentence for most patients [6]. However,"/>
 <result pre="antiviral drugs available during that time, a diagnosis of HIV" exact="infection" post="was a death sentence for most patients [6]. However,"/>
 <result pre="[7] have been the most vulnerable population to new HIV" exact="infections" post="since they do not have the freedom to control"/>
 <result pre="are also responsible for the ongoing spread of new HIV" exact="infections" post="because of a high preponderance of HIV target cells"/>
 <result pre="pathogenic enveloped viruses including HIV; severe, acute, or Middle East" exact="respiratory" post="syndrome coronaviruses (SARS-CoV or MERS-CoV) [10,11]; hepatitis C virus"/>
 <result pre="enveloped viruses including HIV; severe, acute, or Middle East respiratory" exact="syndrome" post="coronaviruses (SARS-CoV or MERS-CoV) [10,11]; hepatitis C virus (HCV)"/>
 <result pre="or Middle East respiratory syndrome coronaviruses (SARS-CoV or MERS-CoV) [10,11];" exact="hepatitis" post="C virus (HCV) [12,13]; herpes simplex virus 2 (HSV-2)"/>
 <result pre="coronaviruses (SARS-CoV or MERS-CoV) [10,11]; hepatitis C virus (HCV) [12,13];" exact="herpes" post="simplex virus 2 (HSV-2) [14,15]; Japanese encephalitis virus (JEV)"/>
 <result pre="C virus (HCV) [12,13]; herpes simplex virus 2 (HSV-2) [14,15];" exact="Japanese encephalitis" post="virus (JEV) [16,17]; and porcine epidemic diarrhea virus (PEDV)"/>
 <result pre="virus (HCV) [12,13]; herpes simplex virus 2 (HSV-2) [14,15]; Japanese" exact="encephalitis" post="virus (JEV) [16,17]; and porcine epidemic diarrhea virus (PEDV)"/>
 <result pre="(HSV-2) [14,15]; Japanese encephalitis virus (JEV) [16,17]; and porcine epidemic" exact="diarrhea" post="virus (PEDV) [18]. As a result of its broad"/>
 <result pre="great promise as a general microbicidal agent that can prevent" exact="viral" post="transmission and as a therapeutic against enveloped virus-mediated diseases."/>
 <result pre="to be the first clinically proven, preventive measure against various" exact="viral" post="diseases. In this review, the structural characteristics of GRFT"/>
 <result pre="mechanism of action for GRFT is explained in conjunction with" exact="viral" post="resistance profiles to GRFT. In addition, its in vitro"/>
 <result pre="the shores of New Zealand. Researchers at the U.S. National" exact="Cancer" post="Institute first reported its potent cytoprotective activity against HIV-1"/>
 <result pre="of both native and recombinant GRFT against laboratory strains and" exact="primary" post="isolates of T- and M- tropic HIV-1 [5]. In"/>
 <result pre="CD4 receptor-expressing cells [5]. Cell-to-cell fusion and transmission of HIV-1" exact="infection" post="were also blocked by GRFT at similar concentrations [5]."/>
 <result pre="the suppression of HIV transmission, CD4+ T-cell destruction, and ultimately" exact="viral" post="replication through the DC-SIGN mediated pathway [33]. This efficient"/>
 <result pre="fusion peptide inhibitor) [29]. The different glycosylation patterns on the" exact="viral" post="envelope of clade B and clade C gp120 had"/>
 <result pre="T cell destruction [33]. GRFT/antiretroviral combinations also potently inhibited short-term" exact="viral" post="replication in T-cells via DC-SIGN-mediated transmission [33]. Combinations of"/>
 <result pre="might be another plausible mechanism through which GRFT inhibits HIV-1" exact="infection" post="[26]. Since the glycans on HIV-1 gp120 play an"/>
 <result pre="HIV envelope glycoproteins for the successful cross-linking and aggregation of" exact="viral" post="particles [20]. Interestingly, an obligate dimer of GRFT with"/>
 <result pre="HIV-1 [38] could synergize with its antiviral action by blocking" exact="viral" post="entry. To maximize the antiviral synergy caused by GRFT"/>
 <result pre="[36]. Inter-virion aggregation or clustering of HIV-1 gp120 on the" exact="viral" post="membrane was found to be related to neutralization potency"/>
 <result pre="was found to be related to neutralization potency [35]. 6." exact="Resistance" post="Five studies have characterized viral resistance profiles caused by"/>
 <result pre="to neutralization potency [35]. 6. Resistance Five studies have characterized" exact="viral" post="resistance profiles caused by chronic GRFT treatment (Table 5)"/>
 <result pre="Resistance Five studies have characterized viral resistance profiles caused by" exact="chronic" post="GRFT treatment (Table 5) [25,26,31,39,40]. Since the antiviral activity"/>
 <result pre="on disrupting the biological functions of multiple mannose molecules on" exact="viral" post="glycoproteins, a reduction in the glycosylation levels of a"/>
 <result pre="on gp120, a single deglycosylation at N295 or N448 in" exact="primary" post="or T-cell-line-adapted HIV-1 isolates also resulted in marked resistance"/>
 <result pre="changes in the secretion of inflammatory cytokines and chemokines by" exact="epithelial" post="cells and human peripheral blood mononuclear cells (PBMCs) [43]."/>
 <result pre="of inflammatory cytokines and chemokines by epithelial cells and human" exact="peripheral" post="blood mononuclear cells (PBMCs) [43]. In addition, it had"/>
 <result pre="obvious changes were observed in animal fitness, blood chemistry, or" exact="complete" post="blood count parameters in GRFT-treated mice [44]. Interestingly, the"/>
 <result pre="the potential of its versatile in vivo antiviral activity [43]." exact="Chronic" post="intravaginal or systemic administration of 2 mg/kg of GRFT"/>
 <result pre="its versatile in vivo antiviral activity [43]. Chronic intravaginal or" exact="systemic" post="administration of 2 mg/kg of GRFT was also non-toxic"/>
 <result pre="or systemic administration of 2 mg/kg of GRFT was also" exact="non-toxic" post="in mice [44]. GRFT, when administered in gel form,"/>
 <result pre="lymphocytes treated with GRFT [45]. However, following GRFT treatment, reversible" exact="splenomegaly" post="was observed with the activation of certain spleen B"/>
 <result pre="HIV-Env pseudoviruses, was also detected in rat fecal extracts after" exact="chronic" post="oral dosing [46]. The in vivo efficacy of GRFT"/>
 <result pre="the humanized bone marrow-liver-thymus mice which were protected from vaginal" exact="infection" post="with HIV-1 after being treated with recombinant C. crescentus"/>
 <result pre="GRFT [47]. However, GRFT was not orally bioavailable even after" exact="chronic" post="treatment [46]. 9. Large-Scale Production The clinical application of"/>
 <result pre="medium, which led to an approximately 45-fold increase in the" exact="total" post="amount of GRFT per liter with approximately 70% of"/>
 <result pre="for vacuum inoculation [50]. They found that recombinant GRFT is" exact="stable" post="during the storage of plant biomass as silage, which"/>
 <result pre="produce GRFT, which accounted for up to 5% of the" exact="total" post="soluble protein of the plant [53]. They also found"/>
 <result pre="the expressed proteins [55]. 10. A Formulation for Efficient Delivery" exact="Protein" post="stability is critical for long-term maintenance of pharmacological activity."/>
 <result pre="GRFT and dapivirine in vitro [60]. Both drugs showed a" exact="biphasic" post="release with an initial burst phase followed by a"/>
 <result pre="rising dose tolerance was not studied because of the minimal" exact="systemic" post="absorbance of GRFT, which was reported in preclinical studies."/>
 <result pre="program. This program, which was named PREVENT (pre-exposure prevention of" exact="viral" post="entry), aimed to provide a comprehensive set of data"/>
 <result pre="GRFT specifically bound to the SARS-CoV spike glycoprotein and inhibited" exact="viral" post="entry [10]. GRFT also inhibited particles pseudotyped with the"/>
 <result pre="host cells [11]. Preincubation of HCV particles with GRFT prevented" exact="infection" post="of Huh-7 hepatoma cells [13]. Furthermore, GRFT was able"/>
 <result pre="This anti-HCV activity was further demonstrated in vivo when HCV" exact="infection" post="was mitigated in chimeric mice [12]. In this report,"/>
 <result pre="and it showed significant in vivo efficacy by reducing HCV" exact="viral" post="titers in a mouse model system with engrafted human"/>
 <result pre="could occur through an indirect mechanism involving mutations in other" exact="viral" post="proteins [65]. GRFT displayed modest inhibitory activity against HSV-2"/>
 <result pre="modest inhibitory activity against HSV-2 if it was present during" exact="viral" post="entry, but if it was present post-entry, it completely"/>
 <result pre="[14]. These in vitro findings translated into significant protection against" exact="genital herpes" post="in mice treated with a 0.1% griffithsin gel [14]."/>
 <result pre="These in vitro findings translated into significant protection against genital" exact="herpes" post="in mice treated with a 0.1% griffithsin gel [14]."/>
 <result pre="subjects were protected by C. crescentus expressing GRFT after intravaginal" exact="infection" post="with HSV-2 [64]. Levendosky et al. explored the antiviral"/>
 <result pre="JEV with GRFT before inoculation into BHK- 21 cells inhibited" exact="infection" post="in a dose-dependent manner [17]. In vivo experiments showed"/>
 <result pre="vivo experiments showed that GRFT (5 mg/kg) administered intraperitoneally before" exact="virus infection" post="prevented mortality in mice challenged intraperitoneally with a lethal"/>
 <result pre="experiments showed that GRFT (5 mg/kg) administered intraperitoneally before virus" exact="infection" post="prevented mortality in mice challenged intraperitoneally with a lethal"/>
 <result pre="antiviral mechanism, GRFT was shown to bind to JEV glycosylated" exact="viral" post="proteins, specifically the enveloped and pre-mature glycoproteins [16]. In"/>
 <result pre="glycoproteins [16]. In addition, GRFT was able to reduce PEDV" exact="infection" post="in Vero cells [18]. 13. Conclusions Due to its"/>
 <result pre="GRFT will provide a superior way to prevent many transmissible" exact="viral" post="infections. Funding This research was supported by the Basic"/>
 <result pre="Biol. Chem.20102858646865510.1074/jbc.M109.03492620080975 2.O’KeefeB.R.SmeeD.F.TurpinJ.A.SaucedoC.J.GustafsonK.R.MoriT.BlakesleeD.BuckheitR.BoydM.R.Potent anti-influenza activity of cyanovirin-n and interactions with" exact="viral" post="hemagglutininAntimicrobial. Agents Chemother.2003472518252510.1128/AAC.47.8.2518-2525.200312878514 3.HuskensD.FerirG.VermeireK.KehrJ.C.BalzariniJ.DittmannE.ScholsD.Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated"/>
 <result pre="of tenofovir gel, an antiretroviral microbicide, for the prevention of" exact="HIV infection" post="in womenScience20103291168117410.1126/science.119374820643915 8.BeyrerC.BaralS.D.van GriensvenF.GoodreauS.M.ChariyalertsakS.WirtzA.L.BrookmeyerR.Global epidemiology of HIV infection in"/>
 <result pre="tenofovir gel, an antiretroviral microbicide, for the prevention of HIV" exact="infection" post="in womenScience20103291168117410.1126/science.119374820643915 8.BeyrerC.BaralS.D.van GriensvenF.GoodreauS.M.ChariyalertsakS.WirtzA.L.BrookmeyerR.Global epidemiology of HIV infection in"/>
 <result pre="prevention of HIV infection in womenScience20103291168117410.1126/science.119374820643915 8.BeyrerC.BaralS.D.van GriensvenF.GoodreauS.M.ChariyalertsakS.WirtzA.L.BrookmeyerR.Global epidemiology of" exact="HIV infection" post="in men who have sex with menLancet201238036737710.1016/S0140-6736(12)60821-622819660 9.LusvarghiS.BewleyC.A.Griffithsin: An"/>
 <result pre="of HIV infection in womenScience20103291168117410.1126/science.119374820643915 8.BeyrerC.BaralS.D.van GriensvenF.GoodreauS.M.ChariyalertsakS.WirtzA.L.BrookmeyerR.Global epidemiology of HIV" exact="infection" post="in men who have sex with menLancet201238036737710.1016/S0140-6736(12)60821-622819660 9.LusvarghiS.BewleyC.A.Griffithsin: An"/>
 <result pre="against emerging viruses of the family coronaviridaeJ. Virol.2010842511252110.1128/JVI.02322-0920032190 11.MilletJ.K.SeronK.LabittR.N.DanneelsA.PalmerK.E.WhittakerG.R.DubuissonJ.BelouzardS.Middle east" exact="respiratory" post="syndrome coronavirus infection is inhibited by griffithsinAntiviral Res.20161331810.1016/j.antiviral.2016.07.01127424494 12.TakebeY.SaucedoC.J.LundG.UenishiR.HaseS.TsuchiuraT.KnetemanN.RamessarK.TyrrellD.L.ShirakuraM.et"/>
 <result pre="emerging viruses of the family coronaviridaeJ. Virol.2010842511252110.1128/JVI.02322-0920032190 11.MilletJ.K.SeronK.LabittR.N.DanneelsA.PalmerK.E.WhittakerG.R.DubuissonJ.BelouzardS.Middle east respiratory" exact="syndrome" post="coronavirus infection is inhibited by griffithsinAntiviral Res.20161331810.1016/j.antiviral.2016.07.01127424494 12.TakebeY.SaucedoC.J.LundG.UenishiR.HaseS.TsuchiuraT.KnetemanN.RamessarK.TyrrellD.L.ShirakuraM.et al.Antiviral"/>
 <result pre="viruses of the family coronaviridaeJ. Virol.2010842511252110.1128/JVI.02322-0920032190 11.MilletJ.K.SeronK.LabittR.N.DanneelsA.PalmerK.E.WhittakerG.R.DubuissonJ.BelouzardS.Middle east respiratory syndrome" exact="coronavirus infection" post="is inhibited by griffithsinAntiviral Res.20161331810.1016/j.antiviral.2016.07.01127424494 12.TakebeY.SaucedoC.J.LundG.UenishiR.HaseS.TsuchiuraT.KnetemanN.RamessarK.TyrrellD.L.ShirakuraM.et al.Antiviral lectins from"/>
 <result pre="of the family coronaviridaeJ. Virol.2010842511252110.1128/JVI.02322-0920032190 11.MilletJ.K.SeronK.LabittR.N.DanneelsA.PalmerK.E.WhittakerG.R.DubuissonJ.BelouzardS.Middle east respiratory syndrome coronavirus" exact="infection" post="is inhibited by griffithsinAntiviral Res.20161331810.1016/j.antiviral.2016.07.01127424494 12.TakebeY.SaucedoC.J.LundG.UenishiR.HaseS.TsuchiuraT.KnetemanN.RamessarK.TyrrellD.L.ShirakuraM.et al.Antiviral lectins from"/>
 <result pre="algae show potent in vitro and in vivo activity against" exact="hepatitis" post="c virusPLoS ONE20138e6444910.1371/journal.pone.006444923700478 13.MeulemanP.AlbeckaA.BelouzardS.VercauterenK.VerhoyeL.WychowskiC.Leroux-RoelsG.PalmerK.E.DubuissonJ.Griffithsin has antiviral activity against hepatitis"/>
 <result pre="against hepatitis c virusPLoS ONE20138e6444910.1371/journal.pone.006444923700478 13.MeulemanP.AlbeckaA.BelouzardS.VercauterenK.VerhoyeL.WychowskiC.Leroux-RoelsG.PalmerK.E.DubuissonJ.Griffithsin has antiviral activity against" exact="hepatitis" post="C virusAntimicrob. Agents Chemother.2011555159516710.1128/AAC.00633-1121896910 14.NixonB.StefanidouM.MesquitaP.M.FakiogluE.SegarraT.RohanL.HalfordW.PalmerK.E.HeroldB.C.Griffithsin protects mice from genital"/>
 <result pre="against hepatitis C virusAntimicrob. Agents Chemother.2011555159516710.1128/AAC.00633-1121896910 14.NixonB.StefanidouM.MesquitaP.M.FakiogluE.SegarraT.RohanL.HalfordW.PalmerK.E.HeroldB.C.Griffithsin protects mice from" exact="genital herpes" post="by preventing cell-to-cell spreadJ. Virol.2013876257626910.1128/JVI.00012-1323536670 15.LevendoskyK.MizeninaO.MartinelliE.Jean-PierreN.KizimaL.RodriguezA.KleinbeckK.BonnaireT.RobbianiM.ZydowskyT.M.et al.Griffithsin and carrageenan"/>
 <result pre="hepatitis C virusAntimicrob. Agents Chemother.2011555159516710.1128/AAC.00633-1121896910 14.NixonB.StefanidouM.MesquitaP.M.FakiogluE.SegarraT.RohanL.HalfordW.PalmerK.E.HeroldB.C.Griffithsin protects mice from genital" exact="herpes" post="by preventing cell-to-cell spreadJ. Virol.2013876257626910.1128/JVI.00012-1323536670 15.LevendoskyK.MizeninaO.MartinelliE.Jean-PierreN.KizimaL.RodriguezA.KleinbeckK.BonnaireT.RobbianiM.ZydowskyT.M.et al.Griffithsin and carrageenan"/>
 <result pre="cell-to-cell spreadJ. Virol.2013876257626910.1128/JVI.00012-1323536670 15.LevendoskyK.MizeninaO.MartinelliE.Jean-PierreN.KizimaL.RodriguezA.KleinbeckK.BonnaireT.RobbianiM.ZydowskyT.M.et al.Griffithsin and carrageenan combination to target" exact="herpes" post="simplex virus 2 and human papillomavirusAntimicrob. Agents Chemother.2015597290729810.1128/AAC.01816-1526369967 16.IshagH.Z.LiC.WangF.MaoX.Griffithsin"/>
 <result pre="binds to the glycosylated proteins (E and prM) of japanese" exact="encephalitis" post="virus and inhibit its infectionVirus Res.2016215505410.1016/j.virusres.2016.01.01626820432 17.IshagH.Z.LiC.HuangL.SunM.X.WangF.NiB.MalikT.ChenP.Y.MaoX.Griffithsin inhibits japanese"/>
 <result pre="encephalitis virus and inhibit its infectionVirus Res.2016215505410.1016/j.virusres.2016.01.01626820432 17.IshagH.Z.LiC.HuangL.SunM.X.WangF.NiB.MalikT.ChenP.Y.MaoX.Griffithsin inhibits japanese" exact="encephalitis" post="virus infection in vitro and in vivoArch. Virol.201315834935810.1007/s00705-012-1489-223053519 18.LiL.YuX.ZhangH.ChengH.HouL.ZhengQ.HouJ.In"/>
 <result pre="virus and inhibit its infectionVirus Res.2016215505410.1016/j.virusres.2016.01.01626820432 17.IshagH.Z.LiC.HuangL.SunM.X.WangF.NiB.MalikT.ChenP.Y.MaoX.Griffithsin inhibits japanese encephalitis" exact="virus infection" post="in vitro and in vivoArch. Virol.201315834935810.1007/s00705-012-1489-223053519 18.LiL.YuX.ZhangH.ChengH.HouL.ZhengQ.HouJ.In vitro antiviral"/>
 <result pre="and inhibit its infectionVirus Res.2016215505410.1016/j.virusres.2016.01.01626820432 17.IshagH.Z.LiC.HuangL.SunM.X.WangF.NiB.MalikT.ChenP.Y.MaoX.Griffithsin inhibits japanese encephalitis virus" exact="infection" post="in vitro and in vivoArch. Virol.201315834935810.1007/s00705-012-1489-223053519 18.LiL.YuX.ZhangH.ChengH.HouL.ZhengQ.HouJ.In vitro antiviral"/>
 <result pre="Virol.201315834935810.1007/s00705-012-1489-223053519 18.LiL.YuX.ZhangH.ChengH.HouL.ZhengQ.HouJ.In vitro antiviral activity of griffithsin against porcine epidemic" exact="diarrhea" post="virusVirus Genes20195517418110.1007/s11262-019-01633-730637608 19.ZiolkowskaN.E.O’KeefeB.R.MoriT.ZhuC.GiomarelliB.VojdaniF.PalmerK.E.McMahonJ.B.WlodawerA.Domain-swapped structure of the potent antiviral protein"/>
 <result pre="protein griffithsin and its mode of carbohydrate bindingStructure2006141127113510.1016/j.str.2006.05.01716843894 20.MoulaeiT.ShenoyS.R.GiomarelliB.ThomasC.McMahonJ.B.DauterZ.O’KeefeB.R.WlodawerA.Monomerization of" exact="viral" post="entry inhibitor griffithsin elucidates the relationship between multivalent binding"/>
 <result pre="griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV" exact="type 1," post="HIV type 2, and selected carbohydrate-binding agent-resistant HIV type"/>
 <result pre="carbohydrate-binding agents demonstrate superior activity against HIV type 1, HIV" exact="type 2," post="and selected carbohydrate-binding agent-resistant HIV type 1 strainsAIDS Res."/>
 <result pre="type 1, HIV type 2, and selected carbohydrate-binding agent-resistant HIV" exact="type 1" post="strainsAIDS Res. Hum. Retroviruses2012281513152310.1089/aid.2012.002622607556 29.FerirG.PalmerK.E.ScholsD.Synergistic activity profile of griffithsin"/>
 <result pre="transmission of HIV-1PLoS ONE20138e6413210.1371/journal.pone.006413223741304 31.HuB.DuT.LiC.LuoS.LiuY.HuangX.HuQ.Sensitivity of transmitted and founder human" exact="immunodeficiency" post="virus type 1 envelopes to carbohydrate-binding agents griffithsin, cyanovirin-n"/>
 <result pre="HIV-1PLoS ONE20138e6413210.1371/journal.pone.006413223741304 31.HuB.DuT.LiC.LuoS.LiuY.HuangX.HuQ.Sensitivity of transmitted and founder human immunodeficiency virus" exact="type 1" post="envelopes to carbohydrate-binding agents griffithsin, cyanovirin-n and galanthus nivalis"/>
 <result pre="T cellsAntivir. Antiretrovir.2012410310.4172/jaa.1000054 34.BanerjeeK.MichaelE.EgginkD.van MontfortT.LasnikA.B.PalmerK.E.SandersR.W.MooreJ.P.KlasseP.J.Occluding the mannose moieties on human" exact="immunodeficiency" post="virus type 1 gp120 with griffithsin improves the antibody"/>
 <result pre="Antiretrovir.2012410310.4172/jaa.1000054 34.BanerjeeK.MichaelE.EgginkD.van MontfortT.LasnikA.B.PalmerK.E.SandersR.W.MooreJ.P.KlasseP.J.Occluding the mannose moieties on human immunodeficiency virus" exact="type 1" post="gp120 with griffithsin improves the antibody responses to both"/>
 <result pre="and subdomain valency control effects of neutralizing lectins on HIV-1" exact="viral" post="particlesACS Infect. Dis2016288289110.1021/acsinfecdis.6b0013927669574 36.MoulaeiT.AlexandreK.B.ShenoyS.R.MeyersonJ.R.KrumpeL.R.ConstantineB.WilsonJ.BuckheitR.W.Jr.McMahonJ.B.SubramaniamS.et al.Griffithsin tandemers: Flexible and potent"/>
 <result pre="al.Griffithsin tandemers: Flexible and potent lectin inhibitors of the human" exact="immunodeficiency" post="virusRetrovirology201512610.1186/s12977-014-0127-325613831 37.XueJ.HoorelbekeB.KagiampakisI.DemelerB.BalzariniJ.LiwangP.J.The griffithsin dimer is required for high-potency inhibition"/>
 <result pre="40.HuangX.JinW.GriffinG.E.ShattockR.J.HuQ.Removal of two high-mannose N-linked glycans on gp120 renders human" exact="immunodeficiency" post="virus 1 largely resistant to the carbohydrate-binding agent griffithsinJ."/>
 <result pre="potential usesViruses2016833110.3390/v8120331 47.Farr ZuendC.NomelliniJ.F.SmitJ.HorwitzM.S.A caulobacter crescentus microbicide protects from vaginal" exact="infection" post="with HIV-1JR-CSF in humanized bone marrow-liver-thymus miceJ. Virol.20193e00614-1910.1128/JVI.00614-19 48.FuquaJ.L.WangaV.PalmerK.E.Improving"/>
 <result pre="on 5 October 2019) 62.PalmerK.E.Griffithsin-based Rectal Microbicides for Prevention of" exact="Viral" post="Entry (PREVENT)Available online: https://clinicaltrials.gov/ct2/show/NCT04032717?term=griffithsin&amp;amp;rank=2(accessed on 5 October 2019) 63.Developing"/>
 <result pre="al.Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV" exact="infections" post="in vivoNat. Commun.20189388110.1038/s41467-018-06349-030250170 Figure 1 The amino acid sequence"/>
 <result pre="Figure 1 The amino acid sequence of griffithsin (GRFT). Corresponding" exact="secondary" post="β-sheet structures are marked with yellow arrows based on"/>
 <result pre="is weaker than that of mannose [22] Monomeric GRFT 30–0.97" exact="Reduced" post="activity against HIV-1 due to a loss of multivalent"/>
 <result pre="nona-mannosides [20] GRFT with a disrupted carbohydrate-binding site NMR study" exact="Reduced" post="binding to mannose and a weaker correlation between anti-HIV-1"/>
 <result pre="Assay Readout EC50 (nM) CC50 (nM) Ref. Laboratory strains and" exact="primary" post="isolates of T- and M-tropic HIV-1 CEM-SS cells, PBMC,"/>
 <result pre="MT-4, and PBMC p24 &amp;lt;1 &amp;gt;500 [27] HIV-1 subtype C" exact="primary" post="virus isolates TZM-bl and PBMC TZM-bl and p24 0.4"/>
 <result pre="Persistently HIV-infected T cells and noninfected CD4+ target T cells" exact="Giant" post="cell formation 0.087 N/A [28] HIV-1 X4 strain IIIB"/>
 <result pre="Persistently HIV-infected T cells and noninfected CD4+ target T cells" exact="Giant" post="cell formation Efavirenz, tenofovir, raltegravir, and elvitegravir Synergy [28]"/>
 <result pre="resistance mechanisms against GRFT. HIV Type Cell Line Assay Readout" exact="Resistance" post="Mechanism Ref. HIV-1 subtype C primary virus isolates TZM-bl"/>
 <result pre="Cell Line Assay Readout Resistance Mechanism Ref. HIV-1 subtype C" exact="primary" post="virus isolates TZM-bl and PBMC HIV-1 neutralization assay Loss"/>
 <result pre="assay Loss of glycans at positions 234 and 295 [25]" exact="Primary" post="and T-cell-line-adapted HIV-1 isolates TZM-bl cells Env-pseudotyped viruses to"/>
 <result pre="glycan at position 295 and 448 [40] HIV-1 subtype C" exact="primary" post="virus isolates Raji/DC-SIGN cells The DC-SIGN-mediated HIV-1 transfer to"/>
 <result pre="of a glycan at position 234 [38] HIV-1 subtype C" exact="primary" post="virus isolates TheTZM-bl and PBMC HIV-1 neutralization assay in"/>
 <result pre="cytokines and chemokines.No vaginal irritation in rabbits. [45] Human cervical" exact="epithelial" post="cells, cervicovaginal cells, and PBMCs Up to 84 μM"/>
 <result pre="Minimal overall toxicity.Well tolerated.Increase in spleen and liver mass. [41]" exact="Mouse" post="PBMC and BALB/c mice with parenteral administration Up to"/>
 <result pre="mice 108 GRFT-expressing recombinant C. crescentus intravaginally. Protection against HIV-1" exact="infection" post="[47] marinedrugs-17-00567-t008_Table 8Table 8 Large-scale GRFT production methods. N/A"/>
 <result pre="benthamiana 90% of the leaf cells and 50% of the" exact="total" post="soluble protein [50] Transduction with tobacco mosaic virus in"/>
 <result pre="Delivery Route Effects on Delivery Ref. PLGA nanoparticles Vaginal A" exact="biphasic" post="release with an initial burst phase followed by a"/>
</results>
